Aurinia Pharmaceuticals
AUPH
219 hedge funds and large institutions have $497M invested in Aurinia Pharmaceuticals in 2025 Q2 according to their latest regulatory filings, with 34 funds opening new positions, 68 increasing their positions, 64 reducing their positions, and 27 closing their positions.
74% more call options, than puts
Call options by funds: $12.9M | Put options by funds: $7.42M
26% more first-time investments, than exits
New positions opened: 34 | Existing positions closed: 27
2% more funds holding
Funds holding: 214 → 219 (+5)
6% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 64
1% less capital invested
Capital invested by funds: $504M → $497M (-$6.99M)
2.22% less ownership
Funds ownership: 45.65% → 43.43% (-2.2%)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
RAM
Readystate Asset Management
Chicago,
Illinois
|
+$5.27M |
| 2 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$3.45M |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$3.1M |
| 4 |
JF
Jump Financial
Chicago,
Illinois
|
+$2.72M |
| 5 |
RHJA
Rice Hall James & Associates
San Diego,
California
|
+$2.61M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
-$27M |
| 2 |
Goldman Sachs
New York
|
-$9.56M |
| 3 |
BlackRock
New York
|
-$8.55M |
| 4 |
Nuveen
Charlotte,
North Carolina
|
-$7.85M |
| 5 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$4.52M |
AUPH Hedge Fund Activity: Q2 2025 in Review
219 of the 7,613 institutional investors tracked by Wall St. Rank reported a position in Aurinia Pharmaceuticals (AUPH) for Q2 2025, worth a combined $497M — down 1.4% from $504M a quarter earlier.
Buyers outnumbered sellers: 34 funds opened new AUPH positions and 27 closed out — a net gain of 7 holders — while 68 added to existing stakes and 64 trimmed.
The largest buyer was Readystate Asset Management, opening a new position worth an estimated $5.27M. The largest seller was Armistice Capital, cutting an estimated $27M.
- 219 institutional investors held Aurinia Pharmaceuticals (AUPH) as of Q2 2025, up from 214 in Q1 2025.
- Funds reported $497M of Aurinia Pharmaceuticals stock for Q2 2025, down 1.4% quarter-over-quarter.
- 34 funds opened new Aurinia Pharmaceuticals positions in Q2 2025 and 27 closed out, a net change of +7 holders.
- The largest Aurinia Pharmaceuticals buyer in Q2 2025 was Readystate Asset Management, an estimated $5.27M added.
- The largest Aurinia Pharmaceuticals seller in Q2 2025 was Armistice Capital, an estimated $27M sold.
Based on aggregated 13F filings for Q2 2025.